AMLX Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. (AMLX) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.38 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.5% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments.
Sector
Healthcare
Industry
Biotechnology